Press Release

Rheonix Receives EPA Funding to Complete the Development of an Automatic Biosensor for Waterborne Pathogens

Ithaca, N.Y. — March 17, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, announced an additional $120,000 award from the U.S. Environmental Protection Agency (EPA) to further commercialize its biosensor technology for the rapid detection of Cryptosporidium parvum in drinking water. Cryptosporidium parvum can cause serious illness in infants and the elderly. The largest outbreak of the infection occurred in Milwaukee… Read More »

Innovative Biotechnologies Acquired by Privately Held Rheonix, Inc.

GRAND ISLAND, NY — December 31, 2008 — Richard A. Montagna, President of Innovative Biotechnologies International, Inc. ("IBI"), today announced the successful completion of an acquisition by privately-held, Ithaca, NY-based Rheonix, Inc. The ability to integrate the biosensor capabilities of IBI, developed in collaboration with scientists at Cornell University with Rheonix's novel CARD™ (Chemistry And Reagent Device) microfluidic technology, will provide a fully automated "point-of-care" (POC) or "point-of-use" (POU) diagnostic… Read More »

Rheonix, Next-Generation in vitro Diagnostic Systems Company, Receives New York State Innovation Award for Bio International 2008

ITHACA, N.Y. – March 25, 2008 – Rheonix Inc., an in vitro diagnostics systems company pioneering single chip, fully-integrated microfluidic systems for near-patient and point-of-care molecular identification of infectious disease and other applications, announced that it has been selected by the New York State Senate and NYSTAR to receive one of two Innovations Awards, which will support the Company’s participation in Bio International 2008. Founded in 2007, Rheonix’s technology is based… Read More »
Page 8 of 8« First...45678